Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Nalak Das headshot

5 Top Rate-Sensitive Stocks to Buy Amid Fed's Rate Cut Hints

The Fed has said that adoption of more accommodative policy is gaining ground as some economic developments raised concerns about U.S. and global growth.

Why Is BioDelivery (BDSI) Down 12.3% Since Last Earnings Report?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

Swarup Gupta headshot

5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.

All You Need to Know About BioDelivery (BDSI) Rating Upgrade to Buy

BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat

BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.

BioDelivery Sciences International (BDSI) Reports Q1 Loss, Tops Revenue Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of 37.50% and 0.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will BioDelivery Sciences International (BDSI) Report Negative Q1 Earnings? What You Should Know

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for BioDelivery (BDSI) This Earnings Season?

Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

What Makes BioDelivery (BDSI) a New Buy Stock

BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BioDelivery (BDSI) Up 7.8% Since Last Earnings Report: Can It Continue?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know

BioDelivery Sciences International (BDSI) closed at $5.06 in the latest trading session, marking a -1.65% move from the prior day.

BioDelivery Sciences International (BDSI) Gains But Lags Market: What You Should Know

BioDelivery Sciences International (BDSI) closed the most recent trading day at $5.30, moving +0.57% from the previous trading session.

Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.

Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma

Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.

Alnylam Files Application for Hypertension Candidate in UK

Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.

AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Nalak Das headshot

Will the Decade-Old Bull Market Momentum Last? 5 Picks

After a disappointing 2018, in which all the three major stock indexes closed in the red owing to severe volatility, Wall Street has made a spectacular comeback this year.

What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.

What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.

REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.